Inveready Seed Capital and Caja Navarra have acquired a 34% stake in pharmaceutical firm Neurotec Pharma.
Partial exit follows the company's MBO in 2016, backed by a consortium led by Duke Street
Investment in IT consultancy firm is the third from the Munich-based GP's debut fund
P101 invests €3.5m in the company from two vehicles, Programma 102 and co-investment fund ITA500
Fund targets mid-market European companies generating EBITDA of at least €3m and revenues of €30-150m